



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No. JHV-028.01

In re Application of:

Gallagher, M., et al.

Serial No: 10/722,357

Filed: November 24, 2003

For: Target for Therapy of Cognitive
Impairment

Art Unit: 1641

Attorney Document No. JHV-028.01

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: Missing Parts

Sir:

In response to the Notice to File Missing Parts of Nonprovisional Application mailed April 7, 2004, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 16, lines 9-15, and replace it with the following paragraph:

“Aspartate aminotransferase” is used herein to refer to the enzyme (E.C. 2.6.1.1) that catalyzes the conversion of oxaloacetate and glutamate into aspartate and 2-oxoglutarate, and the nucleic acid and homologs (see for example, GenBank accession Nos.: BC000498 or XM_062678, **(Nucleotide and amino acid sequences are shown in SEQ ID NOS 1 and 2, respectively)**) encoding amino acids with aspartate aminotransferase activity. Aspartate aminotransferase is involved in the catabolism of glutamate in the synaptic cleft and extrasynaptic space. Homologs of the foregoing are believed to exist in other mammals, including primates, canines, felines and rodents.